Announcements Trials
Browse Landscape

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Observational 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Ovarian Neoplasms 5Peritoneal Neoplasms 3Fallopian Tube Neoplasms 3Colorectal Neoplasms 2Stomach Neoplasms 1Recurrence 1Postoperative Complications 1Neoplasm, Residual 1High Grade Serous Ovarian 1Gastric Adenocarcinoma 1Clear-cell metastatic renal cell carcinoma 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Appendiceal Neoplasms 1Adrenocortical Carcinoma 1Adenoma, Islet Cell 1

Interventions

Cyclophosphamide 12fludarabine phosphate 7fludarabine 7venetoclax 6blinatumomab 6Cytarabine 5Lenalidomide 4Dexamethasone 4Blood Specimen Collection 4Azacitidine 4obinutuzumab 3Rituximab 3Radiotherapy 3Melphalan 3Immunotherapy, Adoptive 3pembrolizumab 2daratumumab 2Neoadjuvant Therapy 2Idarubicin 2Chemotherapy, Adjuvant 2Capecitabine 2trastuzumab deruxtecan 1tislelizumab 1tisagenlecleucel 1thymoglobulin 1tetrathiomolybdate 1talquetamab 1tagraxofusp 1sacituzumab govitecan 1sabatolimab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasm, Residual × Cytoreduction Surgical Procedures × 1 year × Clear all
NCT07567573 2026-05-05

retroESGO ov1

European Society of Gynaecological Oncology

Completed
11,383 enrolled
Gynecologic

Ovarian Neoplasms, Postoperative Complications, Recurrence, Neoplasm, Residual

Data powered by HemOnc (CC BY 4.0) Colophon âš¡